IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Two Sigma Investments LP

Two Sigma Investments LP decreased its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 15.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 423,774 shares of the company’s stock after selling 74,816 shares during the quarter. Two Sigma Investments LP owned about 0.49% of IDEAYA Biosciences worth $10,891,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. R Squared Ltd acquired a new stake in shares of IDEAYA Biosciences in the fourth quarter valued at $35,000. Daiwa Securities Group Inc. lifted its holdings in shares of IDEAYA Biosciences by 44.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock valued at $72,000 after purchasing an additional 853 shares during the last quarter. KBC Group NV lifted its holdings in shares of IDEAYA Biosciences by 84.6% during the fourth quarter. KBC Group NV now owns 4,197 shares of the company’s stock valued at $108,000 after purchasing an additional 1,923 shares during the last quarter. Cibc World Markets Corp purchased a new stake in shares of IDEAYA Biosciences during the fourth quarter valued at $203,000. Finally, Mariner LLC lifted its holdings in shares of IDEAYA Biosciences by 9.8% during the fourth quarter. Mariner LLC now owns 9,775 shares of the company’s stock valued at $251,000 after purchasing an additional 869 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Trading Up 0.7%

NASDAQ:IDYA opened at $18.82 on Friday. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -5.70 and a beta of 0.26. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $44.42. The business’s fifty day moving average price is $17.65 and its 200 day moving average price is $21.92.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the previous year, the business earned ($0.53) earnings per share. Equities analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IDYA has been the subject of several analyst reports. Stephens reaffirmed an “overweight” rating and set a $50.00 target price on shares of IDEAYA Biosciences in a report on Friday, February 14th. JPMorgan Chase & Co. upped their target price on IDEAYA Biosciences from $63.00 to $66.00 and gave the company an “overweight” rating in a report on Thursday. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.27.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.